MARKET

MRTX

MRTX

Mirati
NASDAQ

Real-time Quotes | Nasdaq Last Sale

196.37
-5.87
-2.90%
Opening 10:41 03/03 EST
OPEN
200.60
PREV CLOSE
202.24
HIGH
200.60
LOW
195.95
VOLUME
36.33K
TURNOVER
--
52 WEEK HIGH
249.42
52 WEEK LOW
66.01
MARKET CAP
9.94B
P/E (TTM)
-24.7062
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
DJ Mirati Therapeutics Is Maintained at Outperform by Oppenheimer
Dow Jones · 1d ago
--Analyst Actions: Oppenheimer Adjusts Mirati Therapeutics PT to $255 From $260, Maintains Outperform Rating
MT Newswires · 2d ago
DJ Mirati Therapeutics Price Target Cut to $255.00/Share From $257.00 by HC Wainwright & Co.
Dow Jones · 2d ago
DJ Mirati Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 2d ago
Analysts Offer Insights on Healthcare Companies: Mirati Therapeutics (MRTX), Sensei Biotherapeutics (SNSE) and MacroGenics (MGNX)
SmarterAnalyst · 2d ago
--Analyst Actions: HC Wainwright & Co. Adjusts Price Target on Mirati Therapeutics to $255 From $257, Maintains Buy Rating
MT Newswires · 2d ago
15 Fastest Growing Biotech Companies in the US
In this article we talk about 15 fastest growing biotech companies in the US. You can skip our detailed analysis of the biotech industry and go to 5 Fastest Growing Biotech Companies in the US. Biotechnology is one of the most consequential domains of the ...
Insider Monkey · 4d ago
BRIEF-Mirati Therapeutics Posts Q4 Loss Per Share $2.08
reuters.com · 5d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MRTX. Analyze the recent business situations of Mirati through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 15 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MRTX stock price target is 247.91 with a high estimate of 300.00 and a low estimate of 195.00.
EPS
Institutional Holdings
Institutions: 376
Institutional Holdings: 61.61M
% Owned: 121.68%
Shares Outstanding: 50.63M
TypeInstitutionsShares
Increased
102
6.25M
New
98
1.65M
Decreased
77
3.42M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.71%
Pharmaceuticals & Medical Research
-1.70%
Key Executives
Chairman/Director
Faheem Hasnain
Chairman/Director
faheem Hasnain
President/Chief Executive Officer/Director
Charles Baum
Chief Operating Officer/Executive Vice President
Daniel Faga
Executive Vice President/Chief Scientific Officer
James Christensen
Executive Vice President
Benjamin Hickey
Senior Vice President/Chief Accounting Officer
Vickie Reed
Other
Joseph Leveque
Independent Director
Bruce Carter
Vice President/Director of Human Resources
Jenny Gizzi
Independent Director
Julie Cherrington
Independent Director
Aaron Davis
Independent Director
Henry Fuchs
Independent Director
Michael Grey
Independent Director
Craig Johnson
Independent Director
Maya Martinez-Davis
  • Dividends
  • Splits
  • Insider Activity
No Data
About MRTX
Mirati Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of targeted oncology products. The Company develops product candidates to address the genetic and immunological promoters of cancer. Its clinical programs consist of two product candidates: MRTX849, a Kirsten Rat Sarcoma (KRAS) G12C inhibitor, and Sitravatinib, a multi-kinase inhibitor. Its KRAS inhibitor program is focused on the discovery and development of small molecule compounds that target KRAS G12C and G12D. MRTX849 is designed to inhibit KRAS G12C mutations which are present in non-small cell lung cancer (NSCLC) adenocarcinoma patients, colorectal cancer (CRC) patients, pancreatic cancer patients, as well as several other difficult-to-treat cancers. Sitravatinib is a spectrum-selective kinase inhibitor designed to inhibit receptor tyrosine kinases (RTKs), including TAM family receptors (TYRO3, Axl, Mer), split family receptors (VEGFR2, KIT) and RET.

Webull offers kinds of Mirati Therapeutics Inc stock information, including NASDAQ:MRTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MRTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MRTX stock methods without spending real money on the virtual paper trading platform.